From StockTwits: 2025-02-27 03:52:14

Novavax Inc. shares rose 2% ahead of earnings report, with analysts expecting a narrower loss and revenue drop of over 70%. The company received a $50 million payment from Sanofi for progress on a children’s COVID-19 vaccine. Another $200 million is expected for the first four Sanofi products using Novavax’s Matrix-M adjuvant. Investors monitor Novavax’s bird flu vaccine efforts amid rising U.S. cases. Retail traders on Stocktwits are optimistic, with sentiment remaining ‘bullish’. Concerns over HHS Secretary Robert F. Kennedy Jr.’s impact on vaccine policy raises uncertainty. Novavax stock is down 10% YTD, with short interest at 21.8%.



Read more at StockTwits: Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr’s HHS Leadership Causes Ripples